Nasus Pharma Reveals Promising Phase 2 Study Results for FMXIN002, a Novel Intranasal Epinephrine Powder Nasus Pharma announces positive results from its Phase 2 study of FMXIN002, a needle-free intranasal epinephrine powder, aimed at treating severe allergies.

Nasus Pharma Reveals Promising Phase 2 Study Results for FMXIN002, a Novel Intranasal Epinephrine Powder #Israel #Tel_Aviv #Nasus_Pharma #FMXIN002 #Anaphylaxis

Nasus Pharma to Showcase Promising Clinical Findings on FMXIN002 at AAAAI 2025 At the upcoming 2025 AAAAI Annual Meeting, Nasus Pharma will reveal significant insights from clinical trials of FMXIN002, a groundbreaking intranasal epinephrine product.

Nasus Pharma to Showcase Promising Clinical Findings on FMXIN002 at AAAAI 2025 #Israel #Tel_Aviv #Allergy_Treatment #Nasus_Pharma #FMXIN002